Cheil Pharma Holdings Holds Regular Meeting of Integrated CP Steering Committee with Affiliates

Promoting Sustainable Management Through Joint Risk Management System Across Three Affiliates

Cheil Pharma Holdings announced on the 26th that it held a regular meeting of the CP (Compliance Program) Steering Committee at its headquarters in Seocho-gu, Seoul, on the 25th, with participation from all affiliates including Cheil Pharmaceutical and Cheil Health Science. During the event, the company also presented awards to departments that demonstrated excellence in the CP risk assessment.

On the 25th, a regular meeting of the CP (Compliance Program) Steering Committee was held at the headquarters of Cheil Pharma Holdings in Seocho-gu, Seoul, with participation from all affiliates including Cheil Pharmaceutical and Cheil Health Science. Cheil Pharma Holdings

This meeting was organized to proactively respond to the increasingly stringent fair trade regulatory environment across the pharmaceutical and biotech industries, and to further enhance the CP management system throughout all affiliates. Cheil Pharma Holdings has continuously conducted risk assessments and improvement activities every year to ensure the effectiveness of the CP system. This year, the focus was on standardizing the CP level among affiliates and elevating the compliance capabilities of the entire organization, which was reflected in the objectives of this meeting.

During the meeting, participants shared the latest trends in relevant laws, including key fair trade issues such as the applicability of the Subcontracting Act and abuse of trading positions, thereby raising employees' awareness of voluntary compliance.

In addition, based on the results of the 2025 CP risk assessment, departments with outstanding performance were selected and received commendations from the CEO. The awarded departments were recognized for their detailed risk checks in business operations, regular monitoring, and thorough risk management, all of which contributed to organizational stability and improved performance.

Cheil Pharma Holdings CEO Han Sangcheol, who attended the meeting in person to present the awards, stated, "The true value of the CP system becomes evident in times of crisis, which is why thorough preparation at all times is essential. I ask that all affiliates continue to advance the CP system and solidify the foundation for compliance management that meets global standards through this meeting."

A Cheil Pharma Holdings representative added, "All operating companies, including the holding company Cheil Pharma Holdings, will continue to systematically operate the Compliance Program Steering Committee. We will strictly comply not only with the Pharmaceutical Affairs Act and the Fair Competition Code for Pharmaceutical Transactions, but also with all fair trade regulations, to further establish ourselves as a trusted pharmaceutical company."

This content was produced with the assistance of AI translation services.